Indoramin
Alpha-Adrenoreceptor Antagonists
- Drug class
- Alpha-Adrenoreceptor Antagonists
- Availability
- See label
- Markets covered
- 1
- Products on record
- 4
Overview
Indoramin is an active pharmaceutical ingredient in the Alpha-Adrenoreceptor Antagonists group (C02CA). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 4 | April 17, 2026 |
GBUnited Kingdom· MHRA
4 products
Uses
Conditions for which alpha blockade is indicated. Management of urinary outflow obstruction due to benign prostatic hyperplasia.
How to take
Posology Hyperplasia Adults: 20 mg twice daily Dosage may be increased in 20 mg increments at two-weekly intervals up to max. 100 mg per day if required. Elderly: 20 mg at night may be adequate.
Paediatric population:
Not recommended. Method of administration Oral.
This is not medical advice. Consult a qualified healthcare professional.
Side effects & warnings
Drowsiness or sedation can occur on starting treatment with Indoramin 20 mg tablets, and also if dosage is increased too rapidly. Less commonly, dry mouth, nasal congestion, weight gain, dizziness, failure of ejaculation, depression, fatigue, headache and hypotension (including postural hypotension) with or without syncope may occur.
Rarely, Parkinson’s disease could be exacerbated. Rarely, hypersensitivity reactions including rash and pruritis may occur. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store.
4 Special warnings and special precautions for use Incipient cardiac failure should be controlled before treatment with Indoramin 20 mg tablets. Caution should be observed in prescribing Indoramin 20 mg tablets for patients with hepatic or renal insufficiency.
A few cases of extrapyramidal disorders have been reported in patients treated with Indoramin 20 mg tablets. Caution should be observed in prescribing Indoramin 20 mg tablets in patients with Parkinson's disease. In animals and in the one reported case of overdose in humans, convulsions have occurred.
Due consideration should be given and great caution exercised in the use of Indoramin 20 mg tablets in patients with epilepsy. The 'Intraoperative Floppy Iris Syndrome' (IFIS, a variant of small pupil syndrome) has been observed during cataract surgery in some patients on or previously treated with tamsulosin.
Isolated reports have also been received with other alpha-1 blockers and the possibility of a class effect cannot be excluded. As IFIS may lead to increased procedural complications during the cataract operation current or part use of alpha-1 blockers should be made known to the ophthalmic surgeon in advance of surgery.
Caution should be observed in prescribing Indoramin 20 mg tablets for patients with a history of depression. Clearance of Indoramin 20 mg tablets may be affected in elderly. A reduced dose, and/or reduced frequency of dosing may be sufficient in some elderly patients.
Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.
This is not medical advice. Consult a qualified healthcare professional.
Who should not take it
1. Patients with established heart failure. Patients already under treatment with a monoamine oxidase inhibitor.
This is not medical advice. Consult a qualified healthcare professional.
Sources & citations
- [1]MHRA (UK) · PL045690473 · revised April 17, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.